YL-13027 + HY-0102 + gemcitabine + nab-paclitaxel

A four-drug combination regimen including **YL-13027** (a small molecule and potent, selective inhibitor of **transforming growth factor beta receptor 1 (TGFβR1)**), **HY-0102** (an investigational antibody with ongoing evaluation in solid tumors), **gemcitabine** (a nucleoside analog and DNA synthesis inhibitor used in chemotherapy), and **nab-paclitaxel** (albumin-bound paclitaxel, a microtubule inhibitor). This combination is being researched for the treatment of refractory or metastatic pancreatic cancer. The regimen aims to enhance antitumor responses by targeting TGFβ signaling (via YL-13027), immune modulation/other targets (via HY-0102, specific target not established), disrupting DNA synthesis (gemcitabine), and inhibiting mitosis (nab-paclitaxel). YL-13027 and HY-0102 are both under early-phase investigation, with several ongoing clinical trials assessing their safety and efficacy in combination with gemcitabine and nab-paclitaxel in advanced or metastatic pancreatic cancer and other advanced solid tumors[1][3][5][7].

Other names

paclitaxel albumin-boundAbraxanegemcitabine